tailieunhanh - Báo cáo khoa học: "Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy. | Yoon et al. Radiation Oncology 2010 5 78 http content 5 1 78 RADIATION ONCOLOGY RESEARCH Open Access Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy 1 1 1 1 1 Sang Min Yoon 1 Kyung Hwan Shin Joo-Young Kim Sang Soo Seo Sang-Yoon Park Sung Ho Moon Kwan Ho Cho1 Abstract Background To investigate the significance of monitoring the levels of the serum squamous cell carcinoma antigen SCC-Ag for the detection of recurrent disease in patients with cervical cancer treated by concurrent chemoradiotherapy. Methods The records of 112 patients with cervical cancer were reviewed. Serum SCC-Ag levels were measured at regular follow-up visits. A SCC-Ag level of 2 ng mL was considered the upper limit of normal. Biochemical failure was defined as two consecutively increasing SCC-Ag values above normal. Recurrent disease was confirmed by histologic and radiographic studies. Results Eighteen patients 16 developed recurrent disease. Sixteen patients had initially elevated SCC-Ag posttreatment normalization of SCC-Ag and tumor recurrence. The SCC-Ag difference ASCC-Ag defined as the difference between the last value after two consecutively increases above normal and the value immediately before the elevation had good clinical performance in predicting cancer recurrence. The cutoff value of ASCC-Ag was ng mL. Conclusions SCC-Ag is a relatively good method for the detection of disease recurrence in patients with cervical cancer who were treated by concurrent chemoradiotherapy. Background Radiotherapy has maintained its place as the cornerstone of therapy for many decades for uterine cervical cancer. Recently the results of several randomized trials have recommended the concomitant administration of chemotherapy and radiotherapy as a standard treatment for patients with locally advanced cervical cancer 1-3 . Although this combination treatment plays a role in .